Tuesday | Wednesday | Thursday | Friday | Saturday
WEDNESDAY, DECEMBER 11, 2019
7:00 am - 5:15 pm Registration - Main Lobby  
     
7:00 am - 8:00 am Continental Breakfast - Hall 2  
     
8:00 am - 8:15 am WELCOME AND OPENING REMARKS – Hall 3
Carlos L. Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX

Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX

C. Kent Osborne, MD
Baylor College of Medicine
Houston, TX
 
     
8:15 am - 8:45 am PLENARY LECTURE 1 - Hall 3  

Stromal Cells and Matrix Remodeling as Essential Regulators of the Tumor Microenvironment 
Ellen Puré, PhD
University of Pennsylvania
Philadelphia, PA
 
                            
8:45 am - 11:15 am

GENERAL SESSION 1 – Hall 3
Moderator: TBD

 
     
8:45 am GS1-01.  Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB)
 
                           Murthy R, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz S, Lin N, Borges V, Ambramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Mueller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey L, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels M, Walker L, Feng W, Winer E. MD Anderson Cancer Center, Houston, TX; Peter MacCallum Cancer Centre, Melbourne, Australia; The Royal Marsden NHS Foundation Trust, London, United Kingdom; Winship Cancer Institute, Atlanta, GA; Tennessee Oncology – Nashville, Nashville, TN; UCLA Medical Center/Jonsson Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber Cancer Institute, Boston, MA; University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, CO; Vanderbilt University Medical Center, Nashville, TN; Duke Cancer Institute, Durham, NC; University Health Network, Princess Margaret Hospital, Toronto, ON, Canada; Hospital General Vall D'Hebron, Barcelona, Spain; Sygehus Lillebaelt - Vejle Sygehus, Velje, Denmark; Centre Léon Bérard, Lyon, France; Rambam Health Care Campus, Haifa, Israel; Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany; Hospital Cuf Descobertas R. Mário Botas, Lisbon, Portugal; Cliniques universitaires Saint-Luc, Brussels, Belgium; 3rd Medical Department, Paracelsus Medical University Salzburg; Salzburg Cancer Research Institute-CCCIT; Cancer Cluster Salzburg, Salzburg, Austria; Edinburgh Cancer Research Centre, Edinburgh, United Kingdom; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Istituto Europeo di Oncologia, Milan, Italy; British Columbia Cancer Agency - Vancouver Centre, Vancouver, BC, Canada; German Breast Group, Neu-Isenburg, Germany; Stanford Cancer Institute, Palo Alto, CA; Seattle Genetics, Bothell, WA.  
     
9:00 am

GS1-02. Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis

 
                           Rugo HS, Im S, Cardoso F, Cortes J, Curigliano G, Pegram MD, Musolino A, Bachelot T, Wright GS, De Laurentiis M, Kaufman PA, Pluard T, Ricci F, Salazar LG, Yardley DA, Edlich S, Hong S, Rock E, Gradishar WJ, SOPHIA Study Group.  University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of; Champalimaud Clinical Center/Champalimaud Foundation, Breast Unit, Lisbon, Portugal; IOB Institute of Oncology, Quironsalud Group; Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; University of Milan, European Institute of Oncology IRCCS, Division of Early Drug Development, Milan, Italy; Stanford University/Stanford Cancer Institute, Stanford, CA; University Hospital of Parma, Medical Oncology and Breast Unit, Parma, Italy; Centre Leon Berard, Medical Oncology Department, Lyon, France; Florida Cancer Specialists & Research Institute, New Port Richey, FL; National Cancer Institute “Fondazione Pascale,” Department of Breast and Thoracic Oncology, Naples, Italy; University of Vermont Cancer Center, Breast Oncology, Division of Hematology/Oncology, Burlington, VT; Saint Luke's Cancer Institute, Kansas City, MO; Institut Curie, Paris, France; University of Washington/Seattle Cancer Care Alliance, Seattle, WA; The Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; MacroGenics, Inc., Rockville, MD; Northwestern University, Division of Hematology/Oncology, Chicago, IL.
 
 
9:15 am GS1-03. [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01)  
  Krop IE, Saura C, Yamashita T, Park Y, Kim S, Tamura K, André F,  Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im S, Lee K, Hurvitz S, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Modi S. 
Dana-Farber Cancer Institute, Boston, MA; Vall Hebrón University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; Kanagawa Cancer Center, Yokohama, Japan; Samsung Medical Center, Seoul, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; National Cancer Center Hospital, Tokyo, Japan; Gustave Roussy, Université Paris Sud, Villejuif, France; Aichi Cancer Center Hospital, Nagoya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Kindai University Faculty of Medicine, Osaka and Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan; Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea; The US Oncology Network, Virginia Cancer Specialists, Arlington, VA; Centre Eugène Marquis, Rennes, France; NHO Shikoku Cancer Center, Matsuyama, Japan; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center Korea, Goyang, Republic of Korea; University of California Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, CA; IOB Institute of Oncology, Quiron Group, Madrid & Barcelona and Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain; Daiichi Sankyo, Inc., Basking Ridge, NJ; Memorial Sloan Kettering Cancer Center, New York, NY.
 
     
 9:30 am GS1-04. Interim overall survival analysis of APHINITY (BIG 4-11): A randomised multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer  
  Piccart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer MS, Restuccia E, Jerusalem G, Dent S, Reaby L, Bonnefoi H, Krop I, Liu T, Pieńkowski T, Toi M, Wilcken N, Andersson M, Im Y, Tseng L, Lueck H, Colleoni M, Monturus E, Sicoe M, Guillaume S, Bines J, Gelber R, Viale G, Thomssen C. Institut Jules Bordet, Brussels, Belgium; Frontier Science Scotland (Ltd), Inverness, United Kingdom; Breast International Group, Brussels, Belgium; Roche Products Ltd, Welwyn Garden, United Kingdom; University of Texas MD Anderson Cancer Center, Houston, TX; F. Hoffmann-La Roche Ltd, Basel, Switzerland; International Breast Cancer Study Group, CHU Liege and Liege University, Liege, Belgium; Duke Cancer Institute, Durham, NC; Breast Cancer Trials Australia and New Zealand, Newcastle, Australia; Institute Bergonié, Bordeaux, France; Dana-Farber Cancer Institute, Boston, MA; National Health Research Institutes, Zhunan, Taiwan; Oncology and Hematology Dept. Postgraduate Medical Education Center, Warsaw, Poland; Kyoto University, Kyoto, Japan; Westmead Hospital, University of Sydney, Westmead Cancer Care Centre, Sydney, Australia; Rigshospitalet University Hospital, Copenhagen, Denmark; Samsung Medical Center, Seoul, Korea, Republic of; Taipei-Veterans General Hospital, Taipei, Taiwan; Gynäkologisch-Onkologische Praxis Hannover, Hannover, Germany; Division of Medical Senology, European Institute of Oncology, Milan, Italy; Instituto Nacional de Câncer, Rio de Janeiro, Brazil; University of Milan, European Institute of Oncology, Milan, Italy; Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.  
     
9:45 am

GS1-05. Tbcrc 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT)

 
                           Tolaney SM, Trippa L, Barry W, Hu J, Dang C, Yardley D, Isakoff S, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff A, Reeder-Hayes K, Rugo H, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett M, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz R, Demeo M, Partridge A, Burstein H, Winer EP, Krop I. Dana-Farber Cancer Institute, Boston, MA; Dana-Farber, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; Sarah Cannon Cancer Center, Nashville, TN; Massachusetts General Hospital, Boston, MA; MD Anderson, Houston, TX; Dana-Farber Cancer Institute, South Weymouth, MA; Washington University, St. Louis, MO; New Hampshire Oncology Hematology, Londonderry, NH; Johns Hopkins University, Baltimore, MD; University of North Carolina, Chapel Hill, NC; University of California San Francisco, San Francisco, CA; Ohio State University, Columbus, OH; St. Luke's Mountain States Tumor Institute, Boise, ID; Florida Cancer Specialists, Ft. Meyers, FL; University of Washington, Seattle, WA; Dana-Farber Cancer Institute, Milford, MA; Northwell Health, New Hyde Park, NY; New Hampshire Hematology Oncology, Concord, NH; Indiana University, Indianapolis, IN; Eastern Maine Medical Center, Bangor, ME; Duke Cancer Institute, Durham, NC; Loyola University, Maywood, IL; Hartford HealthCare Cancer Institute, Hartford, CT; Beth Israel Deaconess Medical Center, Boston, MA; Lowell General Hospital, Lowell, MA; University of Chicago, Chicago, IL; University of Pittsburgh Medical Center, Pittsburgh, PA.
 
     
10:00 am GS1-06. Discussant
 
  Amy Jo Chien, MD
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
 
     
10:15 am GS1-07.  Effects of capecitabine as part of neo-/adjuvant chemotherapy. A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients
 
                           van Mackelenberg M, Seither F, Möbus V, O'Shaugnessy J, Martin M, Joenssuu H, Untch M, Nitz U, Miralles JJ, Toi M, Bear HD, Muss H, Reimer T, Nekljudova V, Loibl S. Universitätsklinikum Schleswig-Holstein, Kiel, Germany; German Breast Group, Neu-Isenburg, Germany; Hospital Frankfurt Hoechst, Frankfurt, Germany; US Oncology Research, Inc., The Woodlands, TX; Instituto de Investigacion Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; Helsinki University Central Hospital, Helsinki, Finland; Helios Kliniken Berlin-Buch, Berlin, Germany; Breast Center Niederrhein, Evangelical Hospital Johanniter Bethesda, Mönchengladbach, Germany; Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Division of Surgical Oncology, Massey Cancer Center, Virginia Commonwealth University, VCU Health, Richmond, VA; University of North Carolina at Chapel Hill,, Chapel Hill, NC; Kliniken Südstadt, Rostock, Germany  
     
 10:30 am GS1-08 Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (cbcsg010): An open-label, randomised, multicentre, phase 3 trial  
  Li J, Yu K, Pang D, Wang C, Jiang J, Yang S, Liu Y, Fu P, Sheng Y, Zhang G, Cao Y, He Q, Cui S, Wang X, Ren G, Li X, Yu S, Liu P, Tang J, Wang O, Fan Z, Jiang G, Zhang J, Shao Z, Chinese Breast Cancer Study Group (CBCSG) 010.  Department of Breast Surgery, Fudan University Shanghai Cancer Center, and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; Department of Breast Surgery, The Third Affiliated Hospital of Harbin Medical University, Harbin, China; Department of Breast Surgery, Jinlin Cancer Hospital & Institute, Changchun, China; Department of Breast Surgery, South West Hospital, Chongqing, China; Department of Breast Surgery, Gansu Cancer Hospital, Lanzhou, China; Department of Breast Surgery, The Fourth Clinical Medical College of Hebei Medical University, Shijiazhuang, China; Department of Breast Surgery, Zhejiang First Hospital, Hangzhou, China; Department of Breast Surgery, Changhai Hospital of Shanghai, Shanghai, China; Department of Breast Surgery, Cancer Hospital of Shantou Medical College, Shantou, China; Department of Breast Surgery, The Third Affiliated Hospital of Nanchang University, Nanchang, China; Department of Breast Surgery, The International Peace Maternity & Child Health Hospital of China Welfare Institute, Shanghai, China; Department of Breast Surgery, Henan Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou, China; Department of Breast Surgery, The Second Affiliated Hospital of Medical College of Xi’An Jiaotong University, Xi’an, China; Department of Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Department of Breast Surgery, Shanxi Cancer Hospital, Taiyuan, China; Department of Oncology, Eastern Hospital of Suzhou Municipal Hospital, Suzhou, China; Department of Breast Surgery, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China; Department of Breast Surgery, Jiangsu Cancer Hospital, Suzhou, Jiangsu, China; Department of Oncology, The First Hospital of Wenzhou Medical College, Wenzhou, China; Department of Breast Surgery, The First Hospital of Jilin University, Changchun, China; Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China; Department of Breast Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.  
     
 10:45 am GS1-09 Addition of S-1 to endocrine therapy in the post-operative adjuvant treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative primary breast cancer: A multicenter, open-label, phase 3 randomized trial (POTENT trial)  
  Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Kinoshita T, Kai Y, Kitada M, Sato Y, Jimbo K, Sato N, Ishiguro H, Takada M, Ohashi Y, Ohno S.  Kyoto University Hospital, Kyoto, Japan; Kyorin University Hospital, Mitaka, Japan; Tohoku University, Sendai, Japan; Cancer Institute Hospital, Tokyo, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; NHO Osaka National Hospital, Osaka, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Fukushima Medical University, Fukushima, Japan; Saitama Medical University International Medical Center, Hidaka, Japan; NHO Shikoku Cancer Center, Matsuyama, Japan; Kansai Medial University Hospital, Hirakata, Japan; NHO Tokyo Medical Center, Tokyo, Japan; Ueo Breast Surgery Clinic, Oita, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; NHO Nagoya Medical Center, Nagoya, Japan; National Cancer Center Hospital, Tokyo, Japan; Niigata Cancer Center Hospital, Niigata, Japan; International University of Health and Welfare Hospital, Nasushiobara, Japan; Chuo University, Tokyo, Japan.  
     
 11:00 am GS1-10 Discussant  
  Priyanka Sharma, MD
University of Kansas Medical Center
Westwood, KS
 
     
11:15 am - 12:00 pm WILLIAM L. MCGUIRE MEMORIAL LECTURE - Hall 3  
 

What Would Bill Think?
Joseph Sparano, MD
Montefiore Medical Center
Bronx, NY

 
     
12:00 pm - 1:00 pm BREAK  
     
12:00 pm - 1:00 pm  CAREER DEVELOPMENT FORUM - Room 304
Limited to 200 participants; registrations will be accepted on a first-come, first-served basis and are free of charge.  Badges are required and will be scanned at door for registration.
Attendees should prepare to visit 3-4 tables during the session.  Attendees will be asked to rotate tables every 20 minutes.
 
  Introduction Discussion
12:00 ‐12:05 pm
Eric Winer, Dana-Farber Cancer Institute, Boston, MA   

Mentoring Roundtables
12:05 ‐1:00 pm 
 
  Balancing Research and Clinical Practice (Clinical) 
How to Engage Clinicians in Your Research (Laboratory) 
Becoming a Successful Clinical Trialist (Clinical) 
Careers in Industry
Careers in Translational Research (Clinical) 
Careers in Translational Research (Laboratory) 
Funding Your Own Research 
Making the Transition from Fellowship to Faculty (Clinical) 
Making the Transition from Fellowship to Faculty (Laboratory)  
Negotiating a Job Offer or Promotion 
Team Science: Values, Challenges, and How to Get Started 
Competing for Your Time: Grants versus Publications 
Burnout & Resilience 
     
1:00 pm - 2:00 pm CLINICAL SCIENCE FORUM - Stars at Night Ballroom 3&4 - 3rd Level  
 

Frontiers in HER2 Positive Breast Cancer
Moderator: Sibylle Loibl, MD
German Breast Group
Frankfurt, GERMANY

Origins and clinical implications of HER2 heterogeneity
Andrea L. Richardson, MD, PhD
Johns Hopkins Medicine
Baltimore, MD

Emerging therapies for HER2 positive breast cancer
Shanu Modi, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Systemic therapy for breast cancer brain metastases
Nancy U. Lin, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

 
     
1:00 pm - 2:00 pm BASIC SCIENCE FORUM - Stars at Night Ballroom 1&2 - 3rd Level  
 

RNA Rewiring in Breast Cancer Progression
Moderator: Chonghui Cheng, MD, PhD
Baylor College of Medicine
Houston, TX

RNA methylation in human cancer
Chuan He, PhD
University of Chicago
Chicago, IL

Genome regulation by long noncoding RNA genes
Howard Chang, MD, PhD
Stanford University
Stanford, CA

 
  

2:15 pm - 3:15 pm

SUSAN G. KOMEN® BRINKER AWARDS FOR SCIENTIFIC DISTINCTION LECTURES – Hall 3

 
  SUSAN G. KOMEN® BRINKER AWARD FOR SCIENTIFIC DISTINCTION IN BASIC SCIENCE 
 
  Deciphering Stem and Progenitor Cells to Understand Breast Cancer
Jane Visvader, PhD and Geoffrey Lindeman, MBBS, FRACP, PhD
The Walter and Eliza Hall Institute (WEHI)
Melbourne, AUSTRALIA
 
  SUSAN G. KOMEN® BRINKER AWARD FOR SCIENTIFIC DISTINCTION IN CLINICAL RESEARCH 
 
  The Molecular Etiology of Luminal-Type Breast Cancer
Matthew J. Ellis,  MB BChir, BSc, PhD, FRCP
Baylor College of Medicine
Houston, TX
 
3:15 pm - 5:00 pm

GENERAL SESSION 2 – Hall 3
Moderator: TBD

 
3:15 pm GS2-01. High levels of interferon-response gene signatures are associated with de novo and acquired resistance to CDK4/6 inhibitors in ER+ breast cancer  
                          

De Angelis C, Fu X, Cataldo M, Nardone A, Jansen VM, Veeraraghavan J, Nanda S, Qin L, Sethunath V, Pereira R, Benelli M, Migliaccio I, Malorni L, Donaldson J, Selenica P, Brown DN, Weigelt B, Reis-Filho JS, Park BH, Hurvitz SA, Slamon DJ, Rimawi MF, Jeselsohn R, Osborne K, Schiff R.  Baylor College of Medicine, Houston, TX; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Eli Lilly and Company, Indianapolis, IN; "Sandro Pitigliani" Oncology Department, Hospital of Prato, Azienda USL Toscana Centro, Prato, Italy; Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY; University of California, Los Angeles, Los Angeles, CA.

 
     
3:30 pm GS2-02. Acquired activating mutations in RTKs confer endocrine resistance in ER+ metastatic breast cancer through ER-reprogramming, MAPK signaling, and an induced stem-like cell state  
  Cohen O, Mao P, Nayar U, Buendia-Bue JE, Kim D, Jain E, Helvie K, Abravanel D, Kowalski KJ, Kapstad C, Freeman S, Adalsteinsson V, Wander SA, Waks AG, Getz G, Regev A, Winer EP, Lin NU, Wagle N. Dana-Farber Cancer Institute, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA.  
     
3:45 pm GS2-03. The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer
 
  Lim E. Hickey TE, Selth LA, Chia KM, Milioli HH, Roden D, Laven-Law G, Jindal S, Hui M, Ebrahimie E, Birrell SN, Stelloo S, Caldon CE, Finlay-Schultz J, Abdel-Fatah TM, Ellis IO, Zwart W, Palmieri C, Sartorius CA, Swarbrick A, Carroll JS, Tilley WD.  Garvan Institute of Medical Research, University of New South Wales, Sydney, NSW, Australia; Dame Roma Mitchell Cancer Research Laboratory, University of Adelaide, Adelaide, Australia; Oncode Institute, Netherlands Cancer Institute, Amsterdam, Netherlands; University of Colorado, Aurora, CO; University of Liverpool, Liverpool, United Kingdom; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.  
     
4:00 pm  GS2-04. Microscaled proteogenomic methods for precision oncology

 
  Satpathy S, Jaehnig E, Karsten K, Kim B, Saltzman A, Chan D, Holloway K, Anurag M, Huang C, Singh P, Gao A, Namai N, Dou Y, Wen B, Vasaikar S, Mutch D, Watson M, Ma C, Ademuyiwa F, Rimawi M, Hoog J, Jacobs S, Malovannaya A, Hyslop T, Mani D, Perou C, Miles G, Zhang B, Gillette M, Carr S, Ellis M. Broad Institute of MIT and Harvard, Boston, MA; Baylor College of Medicine, Houston, TX; Siteman Comprehensive Cancer Center and Washington University School of Medicine, St. Louis, MO; National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation, Pittsburgh, PA; Duke University Medical Center, Durham, NC; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.  
     
4:15 pm GS2-05. Primary results of SOLTI-1402/CORALLEEN phase 2 trial of neoadjuvant ribociclib plus letrozole versus chemotherapy in PAM50 Luminal B early breast cancer: An open-label, multicenter, two-arm, randomized study  
                           Gavilá J, Saura C, Pascual T, Hernando C, Muñoz M, Paré L, González Farré B, Fernandez P, Galván P, González Farré X, Oliveira M, Gil Gil M, Arumi M, Ferrer Tur N, Montaño A, Izarzugaza Y, Llombart Cussac A, Bratos R, González S, Martínez E, Hoyos S, Rojas B, Virizuela J, Ortega V, López R, Céliz P, Ciruelos E, Villagrasa P, Prat A.  Instituto Valenciano de Oncología, Valencia, Spain; Vall d' Hebron University Hospital, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Hospital General de Catalunya, Barcelona, Spain; Institut Catala d’ Oncologia Hospitalet, Hospitalet de Llobregat, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitario Fundación Jimenes Díaz, Madrid, Spain; Hospital Universitario Arnau de Vilanova, Valencia, Spain; Centro Oncológico Internacional MD Anderson, Madrid, Spain; Hospital San Pedro de Alcántara, Cáceres, Spain; Consorcio Hospitalario Provincial de Castellón, Castellón de la Plana, Spain; Hospital Rey Juan Carlos, Madrid, Spain; Centro Integral Oncológico Clara Campal, Madrid, Spain; Hospital Virgen Macarena, Sevilla, Spain; Fundación Privada Asil de Granollers, Barcelona, Spain; Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain; Hospital 12 de Octubre, Madrid, Spain.  
     
4:30 pm GS2-06. Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs)

  Martín M, Zielinski C, Ruíz-Borrego M, Carrasco E, Ciruelos E, Muñoz M, Bermejo B, Margeli M, Turner N, Casas M, Antón A, Csöszi T, Corsaro M, Murillo L, Morales S, Alba E, Bartlett CH, Koehler M, Guerrero A, Kahan Z, Gil-Gil M. Instituto de Investigación Sanitaria Gregorio Marañón. CIBERONC-ISCIII. GEICAM Spanish Breast Cancer Group, Madrid, Spain; Vienna Cancer Center, Medical University Vienna and Vienna Hospital Association. Central European Cooperative Oncology Group (CECOG), Viena, Austria; Hospital Universitario Virgen del Rocío. GEICAM Spanish Breast Cancer Group, Sevilla, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Hospital Universitario 12 de Octubre. GEICAM Spanish Breast Cancer Group, Madrid, Spain; Hospital Universitari Clinic de Barcelona. Spanish Breast Cancer Group, Barcelona, Spain; Clínico Universitario de Valencia, INCLIVA Valencia. CIBERONC-ISCIII. GEICAM Spanish Breast Cancer Group, Valencia, Spain; ARGO Group, Catalan Institut of Oncology, Hospital Universitari Germans Trias i Pujol, Badalona. GEICAM Spanish Breast Cancer Group, Barcelona, Spain; Institute of Cancer Research and Royal Marsden, London, United Kingdom; Hospital Universitario Miguel Servet. GEICAM Spanish Breast Cancer Group, Zaragoza, Spain; Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Rendelőintézet, Szolnok, Hungary; Pfizer Inc, Milan, Italy; Hospital Clínico de Zaragoza Lozano Blesa. GEICAM Spanish Breast Cancer Group, Zaragoza, Spain; Hospital Universitario Arnau de Vilanova. GEICAM Spanish Breast Cancer Group, Lleida, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, ES; 18Instituto de Investigación Biomédica de Málaga, IBIMA. CIBERONC-ISCIII. GEICAM Spanish Breast Cancer Group, Málaga, Spain; Pfizer Inc (during study conduct), New York, NY; Repare Therapeutics, Cambridge, MA; Instituto Valenciano de Oncologia. GEICAM Spanish Breast Cancer Group, Valencia, Spain; Department of Oncotherapy, University of Szeged, Szeged, Hungary; Institut Catalá d’Oncologia (ICO), L’Hospitalet de Llobregat. GEICAM Spanish Breast Cancer Group, Barcelona, Spain.  
     
4:45 pm GS2-07. TBD  
     
5:00 pm - 7:00 pm

SPOTLIGHT SESSION 1: Immunotherapy in Breast Cancer: New Directions – Hemisfair Ballroom - 3rd Level

Chair: Hope Rugo, MD
UCSF Medical Center
San Francisco, CA

Discussants:

Valentina Guarneri, MD
University of Padova
Padova, ITALY

Valentina Hoyos, MD
Baylor College of Medicine
Houston, TX

 
                          
 
5:00 pm - 7:00 pm SPOTLIGHT SESSION 2: CDK4/6 Inhibitors Resistance and Biomarkers - Stars at Night Ballroom 1&2 - 3rd Level
Chair: Ratna K. Vadlamudi, PhD
UT Health San Antonio
San Antonio, TX

Discussants:

Resistance
Ben O'Leary, MS
The Institute of Cancer Research
London, UNITED KINGDOM

Biomarkers
Eric S. Knudsen, PhD
Roswell Park Comprehensive Cancer Center
Buffalo, NY

 
     
 5:00 PM - 7:00 PM SPOTLIGHT SESSION 3: Risk/Prevention - Stars at Night Ballroom 3&4 - 3rd Level
Chair: Montserrat Garcia-Closas, PhD
NIH National Cancer Institute
Washington, DC

Discussants:

Genetic susceptibility
Montserrat Garcia-Closas, MD, DrPH
NIH National Cancer Institute
Washington, DC

High risk lesions
Abeer M. Shaaban, MBBCh, MSc, PhD, FRCPath
University of Birmingham
Birmingham, UNITED KINGDOM

Interventions and response biomarkers
Katherine Crew, MD
Columbia University
New York, NY
 
     
5:00 pm - 7:00 pm POSTER SESSION 1 & reception – Hall 1
 
     
 

Detection/Diagnosis

Imaging and Screening - Molecular, Functional, and Novel Imaging
Detection/Diagnosis - Imaging and Screening - Breast Imaging - Other Methods

P1-01
P1-02

     
 

Tumor Cell and Molecular Biology

Animal Models
Ex vivo Models
MicroRNAs and Other Non-coding RNAs
Systems Biology of Breast Cancer
Angiogenesis
Apoptosis and Senescence

P1-03
P1-04
P1-05
P1-06
P1-07
P1-08

     
 

Prognostic and Predictive Factors

Preclinical Studies
Biomarkers Predicting Treatment Sensitivity and Resistance -> Predictive Biomarkers for Chemotherapies

P1-09
P1-10

     
  Epidemiology, Risk, and Prevention

Prevention - Behavioral Interventions
Prevention - Preclinical Studies and Model Systems
Prevention - Clinical Trials
Prevention - Nutritional Studies


P1-11
P1-12
P1-13
P1-14
     
  Psychosocial, Quality of Life, and Educational Aspects

Social and Education Issues - Education
Social and Education Issues -> Advocacy
Other
 

P1-15
P1-16
P1-17


     
  Treatment

Therapeutic Strategies - HER2-Targeted Therapy
Advanced Disease Treatment -> Advanced Therapy - Targeted
Surgery and Radiotherapy: Surgery


P1-18
P1-19
P1-20
     
  Tumor Cell and Molecular Biology

Rescheduled
 

P1-21

     
  Ongoing Trials

Immunotherapy
Adjuvant Therapy
Neoadjuvant Therapy
Endocrine Therapy
Chemotherapy
Gene Therapy
Antibody-Drug Conjugates
New Agents and Combinations
 

OT1-01
OT1-02
OT1-03
OT1-04
OT1-05
OT1-06
OT1-07
OT1-08
     
7:30 pm - 9:30 pm

OPEN SATELLITE EVENT hosted by Research to Practice - Marriott Rivercenter, Grand Ballroom G-M

Data + Perspectives: Clinical Investigators Explore the Current and Future Management of ER-Positive Breast Cancer

For further information and to register for this event, visit  

http://www.researchtopractice.com/Meetings/SA2019

 
     
7:30 pm - 10:00 pm OPEN SATELLITE EVENT hosted by Clinical Care Options - Marriott Rivercenter 

Leveraging Evolving Data Sets to Inform Treatment Decision-Making in HR-Positive, HER2-Negative Advanced Breast Cancer

 
     
 
Tuesday | Wednesday | Thursday | Friday | Saturday
 

S1-04.

S1-04.

Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: primary results from KATHERINE
Limited to 200 participants; registrations will be accepted on a first-come, first-served basis and are free of charge. Badges are required and will be scanned at door for registration.   Attendees should prepare to visit 3-4 tables during the session. Attendees will be asked to rotate tables every 20 minutes.
Limited to 200 participants; registrations will be accepted on a first-come, first-served basis and are free of charge. Badges are required and will be scanned at door for registration.   Attendees should prepare to visit 3-4 tables during the session. Attendees will be asked to rotate tables every 20 minutes.
Limited to 200 participants; registrations will be accepted on a first-come, first-served basis and are free of charge. Badges are required and will be scanned at door for registration.   Attendees should prepare to visit 3-4 tables during the session. Attendees will be asked to rotate tables every 20 minutes.